Bull and Bear

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — both advocates agree the H1 FY26 organic growth print in September 2026 is the single resolving event, and it is four months away.

The Bull case is real: ELIX is the only listed consultancy combining 30%+ adj. EBITDA margins with 30%+ revenue growth, sits on Accenture's multiple for nine times the growth, and runs a non-pyramid model that is genuinely a tailwind in an AI cycle that is hurting every listed peer. The Bear case has equally serious teeth on accounting quality: statutory operating margin has compressed 640bp in two years while the Adjusted EBITDA premium to operating income has widened from 12% to 49%, FCF-after-acquisitions was negative $4.6m in FY25, the company swung from net cash to $32.5m net debt on an $80.8m raise, and tangible book is negative $74.1m. Crucially, both sides name the same number as the test — H1 FY26 organic growth — which means there is no edge buying ahead of it; the watchlist verdict converts to Lean Long if organic prints ≥12% with adj. premium narrowing, and to Avoid if organic falls below 10% with the gap still widening.

Bull Case

Target and trigger. Bull's price target is $15.25 (12.5x Accenture's EV/EBITDA on FY26E adj. EBITDA of $66m, less $32.5m net debt, on ~50.5m shares), 12–18 month horizon. Primary catalyst: H1 FY26 interim (September 2026) showing organic growth ≥12% without a fresh acquisition wave, paired with adj. EBITDA margin holding 28%+. Disconfirming signal: H1 FY26 organic below 10% with adj. margin breaking 25%, or a goodwill impairment on the $232.7m carrying value — either forces exit.

Bear Case

Downside and trigger. Bear's downside target is $6.90 (-30% from $9.85), method 14× FY26 statutory diluted EPS of ~49¢ — a re-rate from the 22× currently paid on Adjusted EPS to the BAH/ICFI mid-teen multiple paid on statutory professional-services EPS, plus a small haircut for goodwill concentration. No impairment is required for the downside; the rerate alone delivers it. Primary trigger: H1 FY26 organic revenue growth printing below 10% without acquisition help. Cover signal: H1 FY26 statutory operating margin reclaims 22%+, FCF-after-acquisitions turns positive (>$20m), AND organic holds 12%+ — all three together kills the thesis.

The Real Debate

Verdict

Watchlist. The Bull case is the more interesting story — a genuine peer-group outlier on the growth/margin combo, a non-pyramid model that is structurally advantaged in an AI cycle, and a founder with $113m at risk owning 22.85% of the company — but Bear carries more weight on the question that matters near-term, which is whether the headline numbers describe the economics. Statutory operating margin has compressed 640bp, FCF-after-acquisitions was negative in FY25, and the company funded its own buyback with $80.8m of new debt; those are facts, not interpretations. The single most important tension is the quality of H1 FY26 organic growth: both Bull and Bear name the same September 2026 print as the resolving event, which means there is genuinely no edge in committing capital before it lands. Bear could still be wrong if H1 FY26 prints ≥12% organic with the adj. premium narrowing, in which case the multiple re-rates and the discount closes — but the reverse scenario is equally available and the balance sheet has just lost its cushion. The condition that flips this verdict is the H1 FY26 interim itself: organic ≥12% without acquisition help and adj. EBITDA premium to operating income narrowing toward FY24 levels moves it to Lean Long; organic below 10% with the gap still widening moves it to Avoid.